Financial News
J&J: Potential HIV vaccine falls short in mid-stage study
August 31, 2021 at 16:30 PM EDT
A potential HIV vaccine being developed by Johnson & Johnson did not provide protection against the virus in a mid-stage study, the drugmaker said Tuesday.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
